Impact of Allogeneic Stem Cell Transplantation in First Complete Remission in Acute Myelogenous Leukemia: A National Population-Based Cohort Study

Allogeneic hematopoietic cell transplantation (allo-HSCT) is a potentially curative treatment strategy for patients with acute myelogenous leukemia (AML) due to the antileukemic effects of cytotoxic conditioning regimens and to the immunologic graft-versus-leukemia effect mediated by donor T cells [1,2]. Until recently, cytogenetic risk classification was the most important criterion when selecting postremission risk-adapted therapy [3], including HSCT in first complete remission (CR1). Most patients achieving CR1 have intermediate-risk cytogenetics, but to date, no truly randomized study has been completed in these patients.

Source: Biology of Blood and Marrow Transplantation - October 16, 2017 Category: Hematology Authors: Lene Sofie Granfeldt Østgård, Jennifer L. Lund, Jan Maxwell Nørgaard, Mette Nørgaard, Bruno C. Medeiros, Bendt Nielsen, Ove Juul Nielsen, Ulrik Malthe Overgaard, Maria Kallenbach, Claus Werenberg Marcher, Anders Hammerich Riis, Henrik Sengeløv Source Type: research